Mutation at the \textit{Evi1} Locus in \textit{Junbo} Mice Causes Susceptibility to Otitis Media

Nicholas Parkinson\textsuperscript{1*}, Rachel E. Hardisty-Hughes\textsuperscript{1*}, Hilda Tateossian\textsuperscript{1}, Hsun-Tien Tsal\textsuperscript{1,2}, Debra Brooker\textsuperscript{1}, Sue Morse\textsuperscript{1}, Zuzanna Lalane\textsuperscript{1}, Francesca MacKenzie\textsuperscript{1}, Martin Fray\textsuperscript{1}, Pete Glenister\textsuperscript{1}, Anne-Marie Woodward\textsuperscript{1}, Sian Polley\textsuperscript{1}, Ivana Barbaric\textsuperscript{1}, Neil Dear\textsuperscript{3}, Tertius A. Hough\textsuperscript{4}, A. Jackie Hunter\textsuperscript{5}, Michael T. Cheeseman\textsuperscript{1,4}, Steve D. M. Brown\textsuperscript{1*}

\textsuperscript{1} Mammalian Genetics Unit, Medical Research Council, Harwell, United Kingdom, \textsuperscript{2}Department of Otorhinolaryngology, Mackay Memorial Hospital, Taipei, Taiwan, \textsuperscript{3}Mammalian Genetics of Disease Group, School of Medicine, University of Sheffield, Sheffield, United Kingdom, \textsuperscript{4}Mary Lyon Centre, Harwell, United Kingdom, \textsuperscript{5}GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Harlow, United Kingdom

Otitis media (OM), inflammation of the middle ear, remains the most common cause of hearing impairment in children. It is also the most common cause of surgery in children in the developed world. There is evidence from studies of the human population and mouse models that there is a significant genetic component predisposing to OM, yet nothing is known about the underlying genetic pathways involved in humans. We identified an N-ethyl-N-nitrosourea-induced dominant mouse mutant \textit{Junbo} with hearing loss due to chronic suppurative OM and otorrhea. This develops from acute OM that arises spontaneously in the postnatal period, with the age of onset and early severity dependent on the microbiological status of the mice and their air quality. We have identified the causal mutation, a missense change in the C-terminal zinc finger region of the transcription factor \textit{Evi1}. This protein is expressed in middle ear basal epithelial cells, fibroblasts, and neutrophil leukocytes at postnatal day 13 and 21 when inflammatory changes are underway. The identification and characterization of the \textit{Junbo} mutant elaborates a novel role for \textit{Evi1} in mammalian disease and implicates a new pathway in genetic predisposition to OM.

Introduction

Otitis media (OM), inflammation of the middle ear, remains the most common cause of hearing impairment in children [1,2]. Acute episodes of OM in infants and children are most often associated with middle ear infections involving the pathogens \textit{Streptococcus pneumoniae} and \textit{Haemophilus influenzae} [3]. Prolonged stimulation of the inflammatory response, along with poor mucociliary clearance, can also lead to the persistence of middle ear fluid giving rise to the clinical presentation of otitis media with effusion [2]. In a substantial portion of children, recurrent episodes of OM or a chronic suppurative OM will develop. The high prevalence of the disease, coupled with its recurrent and chronic nature, accounts for the large number of tympanostomies undertaken in affected children. OM is still the most common cause of surgery in children in the developed world. There is still considerable debate over the etiology of OM and the underlying pathological mechanisms [2]. However, risk factors for OM include craniofacial abnormalities, impaired mucociliary function, and the presence of an inflammatory stimulus, such as bacteria. There is evidence from studies of the human population and mouse models that there is a significant genetic component predisposing to recurrent or chronic OM [4–7], yet little is known about the underlying genetic pathways involved. While several inbred strains are predisposed to the development of OM, their genetic analysis and utility is compounded by the complex genetic bases and the low penetrance of the phenotype [6]. In addition, there are several mouse mutants that demonstrate an OM phenotype, but the OM develops as part of a complex syndrome with a wide spectrum of phenotypes [6]. It will be important to identify and characterize the genes underlying highly penetrant mouse mutants that develop OM in the absence of other diverse pathology and represent appropriate models for OM in the human population.

Large-scale phenotype-driven mouse ENU (N-ethyl-N-nitrosourea) mutagenesis programs provide a rich source of novel mutant phenotypes that are the basis for systematic efforts to identify the genetic basis for diverse disease states [8–10]. One such screen at MRC Harwell, recovered a large number of mutant phenotypes representing ENU-induced mutations at a number of novel loci in the mammalian genome [9]. Mouse models have and continue to play an important role in studying the genetic causes of hearing impairment. A number of mutations have been cloned and have provided us with several profound insights into the critical proteins involved with the development and function of the auditory apparatus at the level of both the middle and inner ears [11,12]. Nevertheless, it is clear that we do not possess mouse mutants for all loci and pathways potentially involved in hearing impairment.

Editor: David Beier, Harvard Medical School, United States of America
Received March 18, 2006; Accepted August 23, 2006; Published October 6, 2006
DOI: 10.1371/journal.pgen.0020149
Copyright: © 2006 Parkinson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abbreviations: DAB, days after birth; dpc, days postcoitum; ENU, N-ethyl-N-nitrosourea; MEC, middle ear cavi; NTHi, nontypeable \textit{Haemophilus influenzae}; OM, otitis media; SPF, specific pathogen-free
* To whom correspondence should be addressed. E-mail: s.brown@har.mrc.ac.uk
\textsuperscript{1} These authors contributed equally to this work.
Synopsis
Otitis media (OM), inflammation of the middle ear, is the most common cause of deafness in children. Although acute episodes of OM in children are associated with middle ear infections, in a substantial portion of cases recurrent episodes of OM, or a chronic suppurative form of OM, will develop. There is evidence from genetic studies of human families that there is a significant genetic component contributing to the development of recurrent and chronic forms of OM. However, the genes involved have not been identified. The authors have identified and characterized mouse mutants that demonstrate chronic OM as a route to identifying genes involved with OM. This study describes one mutant, Junbo, which shares many features with human OM. Junbo develops an acute OM following birth that subsequently develops into a chronic suppurative form of OM. Junbo carries a mutation in the transcription factor gene, Evil. Evil is expressed in a variety of cell types in the middle ear lining when inflammatory changes are underway. The identification of the Junbo mutation implicates a new gene involved in predisposition to OM.

We report the characterization of a new mutant, Junbo, identified in the Harwell mutagenesis program as having a deafness phenotype. Junbo is a model of OM that shares many features with the human condition. Acute OM arises spontaneously in the postnatal period and develops into chronic suppurative OM with otitis media. The underlying molecular basis of this phenotype has been identified as a mutation in the Evil transcription factor causing a nonconservative Asn763Ile change in the second of the two zinc-finger domains in this protein. The Junbo mouse highlights a new role for the transcription factor Evil and provides the first evidence for the genetic pathways involved in the etiology of this complex childhood disease.

Results
Identification, Mapping, and Cloning of the Junbo Mutation
An ENU mutagenesis screen [9] identified a new dominant mutant, Junbo (fbo), with hearing loss. Preliminary phenotyping using a click-box test (see Materials and Methods) of an age-matched cohort derived from the founder mouse indicated that mice demonstrated a hearing loss at ~40 d after birth (DAB). We used a pooling strategy employing DNA from affected mice and genome-wide fluorescent simple sequence length polymorphism-based screening [9,13] to provide an initial map position for the fbo mutation on Chromosome 3. This map position was further refined using additional affected animals to an approximately 1.5-Mb region delineated by the Eif5a2 locus and microsatellite marker D3Mit178. Direct sequence analysis of coding regions within this interval identified an A2288T transversion in the Evil locus, causing a nonconservative Asn763Ile change in the second of the two zinc-finger domains in this protein (Figure 1A and 1B). No other sequence changes were identified in any other coding sequences within the minimal nonrecombinant region containing the mutation.

A knockout allele of Evil has been produced, Eviltm1Mmor [14]. Eviltm1Mmor mice carry a targeted deletion resulting in an isoform-specific null for the longest Evil transcripts, while the Δ324 (shorter) isoform [15,16] remains unaltered. This isoform lacks the final two zinc-finger motifs from the first (N-terminal) DNA-binding domain and consequently is predicted to exhibit altered binding abilities. Characterization of heterozygote mice carrying this targeted mutant failed to uncover any phenotype, while homozygotes show prenatal lethality from presumptive cardiac failure [14]. In addition, these embryos displayed widespread hypopcellularity, most markedly of the cortical mesenchyme, retarded development of the first and second branchial arches, and severely reduced vasculature of the yolk sac. To confirm that the A2318T alteration identified in Evil is responsible for the Junbo phenotype, we undertook a complementation screen between fboþ and Eviltm1Mmorþ mice. 81 live births were produced from crosses of fboþ and Eviltm1Mmorþ mice and all were genotyped. None of the progeny co-inherited the Eviltm1Mmor and the fbo mutations. However, the other expected genotypes were recovered—fbo– (38%), Eviltm1Mmorþ (28%), +/+ (33%)—confirming the allelism of the knockout and Junbo mutant. We established intercrosses between fboþ animals using in vitro fertilization and implantation into wild-type females as fboþ females undergo repeated spontaneous abortion. At 10.5 days postcoitum (dpc), 17% of homozygote mice had small hind limbs, a large pericardial sac, and a malformed forebrain, features demonstrated by the knockout [14]. However, many homozygotes were scored as normal in appearance at this and later stages and proceeded to die between E18.5 and birth, though homozygotes were of comparable body size to wild-type littermates. It appears that though some homozygote embryos may die at 10.5 dpc, others continue to develop unhindered when carried by a wild-type mother. The only other phenotypic feature detected in fboþ mice was an extra digit on one forelimb. fbofbo mice have extra digits on both forelimbs (see Figure 1C).

Pathology Phenotyping of the Junbo Mutant
To determine the cause of the deafness phenotype in Junbo, we performed an initial examination of deaf adult animals and embryonic skeletal preparations (15.5 dpc–18.5 dpc). This revealed no gross morphological defects of the inner ear and ossicular chain or ossification of the temporal bone and tympanic ring in fboþ animals. Dissection of the bullae of seven fboþ mice and four +/+ mice (>130 DAB) revealed that the middle ear cavity (MEC) of mutant mice was filled with exudate, indicative of OM. X-ray analysis revealed that there was no consistent abnormality of bullae shape associated with OM in fboþ mice. Examination of seven fboþ mice (14 bullae, >180 DAB) revealed that 6 fboþ bullae bullae had a normal shape and demonstrated radio opacity, indicating the presence of an effusion in the middle ear, whereas in six fboþ mice, bullae were misshapen and also had an effusion present (demonstrated by radio opacity). Although X-ray imaging is a less sensitive means of diagnosing OM than histology, two fboþ bullae bullae did not demonstrate a radio opacity reflecting the possibility of resolution of a small number of Junbo mice at advanced age (see below). Control ears (two wild-type mice, four bullae) were clear of effusion and presented with a normal bullae shape. We concluded that the presence of abnormally shaped bullae in the Junbo mutant is not necessary for the development of an effusion. We therefore proceeded to study the pathology of the OM in the postnatal period, at weaning, and in the adult, first in
conventionally housed mice of relatively low microbiological status and then in specific pathogen-free (SPF) mice. In conventionally housed mice we found no evidence of inflammation of the embryonic connective tissue or exudation into the MEC in Jbo/þ or wild-type litter mates at 5 DAB. By 13 DAB the MEC is more fully formed and 100% of the Jbo/þ mice and 33% wild-type mice had acute OM (Figure 2A–2D). However, Jbo/þ mice had suppurative exudate in both the MECs, while wild-type mice had unilateral OM, or serous exudation in one ear and suppurative exudation in the contralateral ear. Typical acute inflammatory changes in the MEC mucoperiosteum included edematous polyps (Figure 2E, which may represent unresorbed embryonic connective tissue [17]) and/or bulging sub-epithelial bullae filled with serous fluid, stromal edema, widely patent capillaries, and lymphatics, with variable numbers of infiltrating neutrophil leukocytes. The epithelial covering was formed by small basal cells or ciliated columnar cells (Figure 2F and 2G). A second, milder type of OM occurred in a further 27% of wild-type mice consisting of only focal mucoperiosteal aggregations of neutrophil leucocytes with or

---

**Figure 1.** The *Evi1* Gene Is Mutated in *Junbo* Mice

(a) Sequence analysis of the *Evi1* locus in BALB/c, C3H/HeN, Jbo/þ adult, and Jbo/Jbo embryonic DNA. An A2318T transversion is detected in Jbo/þ and Jbo/Jbo mutants that is not present in either parental substrains.

(b) Schematic of the EVI1 peptide. Ten zinc finger motifs are clustered into two DNA-binding domains, ZF1 and ZF2. EVI1 contains a proline-rich repressor domain between the two sets of zinc fingers and a highly acidic domain at the C-terminus. Expanded peptide sequence across the ninth zinc finger motif shows the high degree of conservation of this region between orthologous proteins from different species: *Mus musculus* (P14404), *Rattus norvegicus* (ENSRNOG0000012645), *Homo sapiens* (Q03112), *Danio rerio* (ENSDARP00000008993), *Fugu rubripes* (ENSDARP00000008993), *Drosophila melanogaster* (CG31753), *Caenorhabditis elegans* (R53.3a). Contact residues are highlighted in yellow, the position of the *Junbo* mutation is highlighted in red.

(c) Extra digits are seen on the forelimbs of both heterozygote and homozygote mice E18.5 (white arrows). In heterozygotes, Jbo/þ, middle panel) an extra digit is observed on either forelimb. The homozygotes, Jbo/Jbo, right panel) have extra digits on both forelimbs. The anterior digit is often reduced in size in the homozygote limbs (red arrow). Wild-type mice, left panel.

DOI: 10.1371/journal.pgen.0020149.g001
without a light neutrophil leukocyte MEC exudation (unpublished data); ~40% wild-type mice had no evidence of OM at this age. Importantly, OM appeared at this stage as part of a more generalized respiratory tract inflammation comprising suppurative rhinitis (Figure 2H) and nasopharyngitis, and multifocal mild alveolitis/interstitial pneumonia with eosinophil leukocytes in perivascular cuffs (Figure 3A and 3B) but without evidence of intralesional bacteria or viral inclusions. There were no significant histological lesions in intestine, liver, pancreas, kidney, heart, thymus, and spleen.

Any postnatal OM had resolved in wild-type mice by weaning (0% incidence at 21 DAB) and OM was exceptional in adults (3% incidence). In contrast, OM was present in 100% of Jbo/+ mice at weaning and occurred in 94% of adult Jbo/+ mice 29 DAB to >180 DAB. Suppurative rhinitis was still present in some Jbo/+ mice examined, but in two the eosinophilic pneumonia was absent or minimal. Large numbers of Gram positive cocci were present in OM exudate at day 21 in ~70% of cases (Figure 3C), suggesting nasopharyngeal staphylococcal and streptococcal flora may play a role in progression of OM, if not its initiation in Jbo/+ mice. There was no evidence of significant proliferation of mucous cells or periodic acid-Schiff-positive mucus in the MEC.

Adult Jbo/+ mice >29 DAB develop bilateral chronic suppurative OM. Chronic middle ear effusions contained variable numbers and proportions of viable and necrotic neutrophil leukocytes and foamy macrophages; bacteria were infrequently present and there were small numbers of multinucleate macrophages, cholesterol clefts, and small amounts of birefringent foreign body (perhaps secondary to perforation of the eardrum). The effusions did not contain significant amounts of periodic acid-Schiff-positive mucus. Chronic changes in inflamed thickened mucoperiosteum include formation of multiple polyps (Figure 2I) covered with fibrous polyps (arrowheads) ×200, hyperplasia of ciliated epithelial cells (arrowhead) and fibrosis of mucoperiosteum stroma ×400, and fibrous thickening of the tympanic membrane, outer ear canal ×400 compared with (l) normal –/+ tympanic membrane, outer ear canal ×400. E, exudate; MP, mucoperiosteum; NC, nasal cavity; NM, nasal mucosa; NS, nasal septum; OEC, outer ear canal; TB, temporal bone; TM, tympanic membrane

DOI: 10.1371/journal.pgen.0020149.g002
trates, and occasional lymphoid nodules. The eustachian tube is patent and can contain exudates, and the epithelial lining can have elevated numbers of mucous cells and intra-

epithelial leukocytes. Fibrous thickening of the eardrum (tymanosclerosis) is common (Figure 2K and 2L). OM was often associated with perforation of the eardrum, possibly providing drainage to account for apparent resolution of a few cases: (6%) of OM in the oldest age group of Jbo/+ mice (> 180 DAB).

The Junbo colony has subsequently been re-derived by embryo transfer into new high-health status facilities (Mary Lyon Centre, Harwell). Mice are housed in individually ventilated cages, and screening shows all FELASA-listed pathogens (see Materials and Methods) have been excluded; 75 cage air changes/h reduce respiratory irritants such as ammonia to < 3 ppm. In SPF conditions, OM in Jbo/+ mice is relatively milder at early time points and is not associated with rhinitis. Typically at 13 DAB there are small numbers of inflammatory cells in the mucoperiosteum and sometimes, light MEC effusion. By 20–22 DAB and 28 DAB, 4% Jbo/+ mice had bilateral OM, 54% unilateral OM, and 42% had very mild or no OM. However, by 54 DAB, Jbo/+ mice (100%) had OM, but in 10% of cases this was unilateral. OM does not occur in pre-weaned wild-type mice and in only 3% (a single case in a 22-DAB mouse) of older wild-type mice.

Comprehensive pathology phenotyping failed to show a consistent pattern of significant organ pathology outside of the middle ear in adult Jbo/+ mice. Specifically there is no evidence of opportunistic infections in sites such as skin, lung, urogenital, or gastrointestinal systems that might be a sign of immune deficiency (see below).

In summary, the microbiological status of the mice and/or air quality affect onset of OM, and under “dirty” conventional conditions even wild-type mice can develop OM in the postnatal period as part of upper respiratory tract disease; however, this resolves in wild-type mice by weaning. In conventionally housed and SPF Jbo/+ mice, OM emerges as a chronic condition.

Immunology and FACS Analysis of SPF Wild-Type and Junbo Mice

There were no significant differences in the antibody responses of Jbo/+ and wild-type control mice to immunization with T-dependent (IgG1 and IgG2a to keyhole limpet hemocyanin) and T-independent (IgGM and IgG3 to pneumococcal polysaccharide type 3) antigens (Table S1). FACS analysis of blood neutrophils identified by the cell surface markers Gr-1 and Mac-1 did not reveal significant differences between levels of immature, mature cell forms, and total circulating blood neutrophils in Jbo/+ and wild-type mice at either 20–22 DAB or 49–58 DAB. However, there was a significantly lower (p = 0.003) ratio of immature forms in the circulating neutrophil pool in 20–22 DAB Jbo/+ mice, but not in 54–58 DAB Jbo/+ mice (Table 1).

Expression of Evi1 in Wild-Type and Junbo Mice

We proceeded to investigate the expression of Evi1 in both embryonic whole-body tissues (E9.5 and at eight intervals through to birth) and postnatal middle ear tissue (13 DAB, 21 DAB) in order to relate the underlying mutation to the Junbo phenotype. We examined expression in wild-type and Jbo/+ mice, but at no time point did we identify any significant differences in expression patterns, up to and including birth, from those described [14,18]. However, in postnatal head tissues, we now find that Evi1 is expressed in nuclei of

**Figure 3.** Histology of the Lung and Middle Ear Exudate in Junbo Mice

(a) 13-d postnatal Jbo/+ lung with perivascular and peribronchiolar cuffs containing Sirius red positive eosinophil leukocytes (arrowhead), bronchiole, pulmonary artery ×400, (b) focal eosinophilic alveolitis (arrowhead) and thickened alveolar septae (open arrowhead) with eosinophil-rich infiltrates. (c) 21-d postnatal Jbo/+ MEC pus with colonies of Gram positive cocci ×600. B, bronchiole; PA, pulmonary artery

DOI: 10.1371/journal.pgen.0020149.g003
myeloid cells in bone marrow, neutrophil leukocytes, fibroblasts, and basal epithelial cells in the inflamed middle ear lining (Figure 4), and that patterns of expression are similar in \( \text{Jbo}/^+ \) and wild-type mice.

**OM Phenotype of the \( \text{Evi1}^{\text{tm1Mmor}/+} \) Mice**

OM is not a prominent feature in \( \text{Evi1}^{\text{tm1Mmor}/+} \) mice. Only one of 12 \( \text{Evi1}^{\text{tm1Mmor}/+} \) mice >68 DAB had OM, and in this single case it was unilateral. OM was not present in 15 wild-type littermates. The absence of OM in \( \text{Evi1}^{\text{tm1Mmor}/+} \) mice, coupled with the presence of extra digits in \( \text{Jbo}/^+ \) and \( \text{Jbo}/\text{Jbo} \) mice, suggests that the \textit{Junbo} mutation may have gain-of-function effects. However, the genetic background of \( \text{Evi1}^{\text{tm1Mmor}/+} \) mice differs from \( \text{Jbo}/^+ \) and \( \text{Jbo}/\text{Jbo} \) mice (see Materials and Methods). In addition, the \( \text{Evi1}^{\text{tm1Mmor}} \) mutation is an isoform-specific null. It is therefore difficult to reach definitive conclusions as to the nature of the \textit{Junbo} mutation (see Discussion).

**Discussion**

A mutation in the \textit{Evi1} transcription factor underlies the development of a chronic suppurative OM in the \textit{Junbo} mutant. Genetic mechanisms appear to interact with microbiological status and environmental conditions, such that SPF \( \text{Jbo}/^+ \) mice with improved air quality have milder early OM. Gnotobiotic studies are planned to investigate the role of nasopharyngeal \textit{Staphylococcus} and \textit{Streptococcus} spp. commensals in OM pathogenesis. The absence of multi-systemic inflammation and opportunistic infections at other sites, and the normal T-dependent and T-independent immune re-

### Table 1. FACS Analysis of the Proportion of Granulocytes in Blood of Wild-Type and \textit{Junbo} Mice

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Age</th>
<th>Granulocytes</th>
<th>Mature NL</th>
<th>Immature NL</th>
<th>Total NL</th>
<th>Immature/Total NL</th>
<th>Mature/Total NL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild-type</td>
<td>20–22</td>
<td>3.99 (0.86–18.32)</td>
<td>0.47 (0.05–3.18)</td>
<td>0.32 (0.02–2.40)</td>
<td>0.78 (0.07–5.58)</td>
<td>0.41 (0.25–0.53)</td>
<td>0.59 (0.47–0.75)</td>
</tr>
<tr>
<td>( \text{Jbo}/^+ )</td>
<td>20–22</td>
<td>5.05 (0.94–14.02)</td>
<td>0.90 (0.07–3.69)</td>
<td>0.38 (0.02–1.17)</td>
<td>1.28 (0.12–4.48)</td>
<td>0.30 (0.06–0.46)</td>
<td>0.70 (0.54–0.94)</td>
</tr>
<tr>
<td>( P )</td>
<td></td>
<td>0.483</td>
<td>0.483</td>
<td>0.582</td>
<td>0.637</td>
<td>0.003</td>
<td>0.235</td>
</tr>
<tr>
<td>Wild-type</td>
<td>49–58</td>
<td>4.89 (2.11–7.96)</td>
<td>1.03 (0.20–2.66)</td>
<td>0.32 (0.09–0.76)</td>
<td>1.35 (0.37–3.42)</td>
<td>0.25 (0.1–0.46)</td>
<td>0.75 (0.54–0.83)</td>
</tr>
<tr>
<td>( \text{Jbo}/^+ )</td>
<td>49–58</td>
<td>6.61 (2.90–10.30)</td>
<td>1.71 (0.33–4.49)</td>
<td>0.33 (0.07–0.83)</td>
<td>2.04 (0.44–5.32)</td>
<td>0.18 (0.05–0.30)</td>
<td>0.82 (0.70–0.95)</td>
</tr>
<tr>
<td>( P )</td>
<td></td>
<td>0.051</td>
<td>0.066</td>
<td>0.646</td>
<td>0.098</td>
<td>0.085</td>
<td>0.085</td>
</tr>
</tbody>
</table>

Figures in the body of the table are mean proportion of cells (and range) in each class.
For 20–22 DAB \( n = 20 \) wild-type, \( n = 17 \) \( \text{Jbo}/^+ \).
For 49–58 DAB \( n = 14 \) wild-type, \( n = 14 \) \( \text{Jbo}/^+ \).
The Wilcoxon sum-of-ranks test was used to test for statistical differences.
DOI: 10.1371/journal.pgen.0020149.t001

### Figure 4. Evi1 Protein Immunostaining in 13-d-Old \( \text{Jbo}/^+ \) and Wild-Type Mice with Acute OM

(a) \( \text{Jbo}/^+ \) positive myeloid cells in temporal bone marrow \( \times 600 \). Note chondrocytes and osteocytes are also strongly positive. (b) \( \text{Jbo}/^+ \) mucoperiosteum has positive neutrophil leukocytes, fibroblasts, and basal epithelial cell nuclei \( \times 600 \). (c) \( +/- \) similar pattern of staining in bone marrow \( \times 600 \) and (d) \( +/- \) inflamed mucoperiosteum \( \times 600 \). B, basal epithelial cell nuclei; C, chondrocyte; F, fibroblast; MC, myeloid cell; N, neutrophil leukocyte; O, osteocyte
DOI: 10.1371/journal.pgen.0020149.g004
in neutrophil leukocytes during OM development. A variety of in vitro studies have highlighted the role of the TGFβ/SMAD pathway on mucin expression and thus underlined the potential importance of this signaling pathway in OM. A loss of Evi1 function could affect TGFβ/SMAD signaling pathways. There are two in vitro studies that suggest that Evi1 mutations could affect mucin expression that might underlie predisposition to OM. Firstly, nontypeable Haemophilus influenzae (NTHi), a known bacterial pathogen involved in human OM, activates Tgfβ receptor-Smad3/4 signaling that together with TLR2-MyD88-TAK1-NIK-IKKβ/IκBζ-dependent activation of NF-κB is known to mediate NTHi-induced MUC2 mucin transcription. Evi1 loss-of-function mutations might lead to a de-repression of the TGFβ/SMAD pathway and an upregulation of MUC2 expression leading to an enhancement of effusive processes as a contributor to OM. Alternatively, it has also been shown that NTHi upregulates MUC5AC mucin production via activation of the TLR2-MyD88-dependant p38 pathway. However, the activation of TGFβ/SMAD signaling by NTHi also leads to down-regulation of p38 activity by inducing MAPK phosphatase-1 and suppressing MUC5AC mucin induction. Thus, in this case loss of Evi1 function and de-repression of the TGFβ/SMAD pathway would presumably lead to increased suppression of MUC5AC mucin induction that may reduce mucociliary defense in suppurative OM. Importantly, the identification of the Junbo mutation now provides in vivo evidence to support the role of these signaling pathways in OM. It will be interesting to explore further the molecular phenotype of the Junbo mutant and to examine whether disregulation of mucin expression is a contributing factor in the development of OM.

Additional levels of complexity of Evi1 function relevant to OM pathogenesis may result from the first (N-terminal) zinc-finger domain binding to a number of putative target genes. Evi1 expression is a contributing factor in the development of OM. It will be interesting to explore further the molecular phenotype of the Junbo mutant and to examine whether disregulation of mucin expression is a contributing factor in the development of OM.
the Evi1 gene and associated pathway members can be considered important candidates for examining the genetic basis for susceptibility to OM in the human population.

Materials and Methods

Mice and deafness screening. The founder mouse carrying the Junbo mutation was generated in a large-scale ENU mutagenesis program at Harwell, United Kingdom [9]. Male BALB/c mice were mutagenized and mated to normal C3H/HeN females, and the offspring were screened for a variety of defects, including deafness and vestibular dysfunction. The Jbo founder was identified because of a lack of a Preyer reflex when presented with a calibrated 20 kHz 90 dB SPL tone burst. For analysis of the phenotype, the colony was maintained on a C3H/HeN background in accordance with Home Office regulations.

Microbiological status of the mice. Junbo mice were originally derived in a conventional facility. Sentinel mice from this colony were seropositive for the FELASA- [37] listed viral agents MHV (judged by histology to be enteropathic strains), Adenovirus II, and TMV, none of which are primary respiratory pathogens [38]. Intestinal flagellates, pinworms, and the opportunistic respiratory pathogen Pasteurella pneumotropica were also common isolates. A number of pathogens known to cause respiratory disease and/or OM in the mouse such as pneumonia virus, Sendai virus, Mycoplasma pulmonis, Streptococcus pneumoniae, and Pseudomonas aeruginosa have not been found over many years in the sentinel screens. Non-FELASA-listed bacteria isolated from the nasopharynx of sentinel mice include Staphylococcus spp., Staphylococcus aureus, Alpha-haemolytic streptococci, and other Streptococcus spp. Junbo mice are now housed in a high-health-status SPF unit in which all FELASA-listed pathogens have been excluded. Non-FELASA nasopharyngeal flora remains the same.

Genetic crosses and mapping. The founder C3H/BL/6J-F1/Jbo/+ mouse was maintained by repeated backcrossing to C3H/HeN. Mutant phenotypes were identified by the lack of a Preyer reflex. 41 DNAs were initially pooled from affected individuals and a genome scan was carried out as described [9,13]. A high-resolution genetic map was constructed using 242 affected progeny N4 and N5 backcross progeny using published microsatellite markers D3Mit90, D3Mit328, D3Mit92, D3Mit203, D3Mit55, D3Mit178, D3Mit151, D3Mit273, D3Mit180, D3Mit239, D3Mit21, D3Mit224, D3Mit182, D3Mit91, and D3Mit242. The genetic map across the Jbo locus was constructed by minimizing the number of recombination events across the region.

The Evi1tm1Mmor mutation was generated in D3 ES cells with subsequent genotyping in F1 mice [14]. Evi1tm1Mmor/+ mice were mated to C3H/HeN mice before crossing to F1 heterozygous mutant progeny along with wild-type and wild-type mice for complementation testing. For phenotypic analysis Evi1tm1Mmor/+ mice were also mated to C3H/HeN mice and F1 heterozygous mutant progeny along with wild-type littermates to assess at appropriate time points.

Pathology, histology, and X-Ray analysis. The onset and time course of the development of the middle ear disease was assessed by histology in conventionally housed postnatal mice 4–5 DAB (five Jbo/+ two +/-); postnatal 13 DAB (13 Jbo/+, 16 +/-); at weaning 21 DAB (seven Jbo/+, 17 +/-); and in adult mice 29 DAB (five Jbo/+, 11 +/-), 44 DAB (six Jbo/+, eight +/-), 130 DAB (seven Jbo/+, nine +/-), and 180–360 DAB (six Jbo/+, three +/-). Representative mice from one to three litters were examined at each time point. In a second study to assess the OM phenotype under SPF conditions, Junbo mice were sampled from an embryo re-derived colony that was housed in individually ventilated cages. The cohorts were as follows: 5 DAB (four Jbo/+, nine +/-), 13 DAB (11 Jbo/+, 19 +/-), 20–22 DAB, 28 DAB (24 Jbo/+, 17 +/-), 49–58 DAB (20 Jbo/+, 18 +/-), and 85–115 DAB (19 Jbo/+), 2 conventionally housed 68 DAB Evi1tm1Mmor/+ mice and 15 same-aged wild-type littermates were also examined for OM.

Histological sections, paraffin embedded in wax, were cut serially and stained with Haemotoxylin and Eosin (H & E). In 13- and 21-DAB mice with OM, transverse sections of the nasal turbinates, dorsal plane sections of the oropharynx, lungs, livers, kidneys, lungs, hearts, intestines, pancreas, and livers were examined by histology. Sections of middle ears, snouts, and lungs from OM cases were examined for bacteria using Gram stain and Sirius red for eosinophil leukocytes. To assess the possibility of opportunistic infections at other body sites, a general pathology screen was performed on four 28-DAB and seven 56-DAB SPF Jbo/+ mice. In addition, a more extensive whole-body pathology analysis of 25 tissues following EMPReSS necropsy SOPs [39] was performed on four female and three male 180-DAB Jbo/+ mice; five female and four male wild-type litter mates were used as controls.

For X-ray analysis, heads were skinned and the brains and mandibles removed, and then the skull was fixed in 10% NBF. After the dorsoventral view was taken, the head was bisected midsagittally and lateromedial views taken. Images were taken on a MX-20 Faxitron X-ray machine (Faxitron X-ray Corporation, Wheeling, Illinois, United States) at 26 kV and 0.3 mA with an exposure time of 5 s.

Immunohistochemistry. Whole embryos (E9.5, E10.5, E11.5, E12.5, E13.5, E16.5, and E18.5) and adult heads (13 DAB and 21 DAB) from wild-type and Jbo/+ mice were used for immunolabelling. 3-µm wax sections were de-paraffinised in xylene substitute and rehydrated through graded ethanol solutions. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide in isopropanol. The sections were microwaved in 10 mM citrate buffer (pH6.0) and rinsed with phosphate-buffered saline at room temperature. The immunostaining was performed using a DAKO (Glostrup, Denmark) autostainer at room temperature. To inhibit the non-specific endogenous biotin staining the Dako Biotin Blocking System was used. A blocking solution of 10% donkey serum (Serotec) was used for 1 h. Goat polyclonal antibody raised against the carboxy terminus of human EVI1 was used in concentration 1:100 (Santa Cruz Biotechnology, Santa Cruz, California, United States) for 1 h. Biotinylated donkey anti-goat antibody (Santa Cruz Biotechnology) and ChemMate Detection Kit (Dako) were used to develop the specific EVI-1 signals. Negative control sections were incubated in donkey serum and processed identically. The slides were counterstained with Haematoxylin.

Skeletal preparations. Embryos were fixed in 95% ethanol and processed through a standard alcin blue and alizarin red bone cartilage staining procedure.

Immunology and FACS analysis in SPF mice. The T-dependent arm of the immune system was assessed by immunization with keyhole limpet hemocyanin and measurement of IgG1 and IgG2a, and the T-independent arm by immunization with pneumococcal polysaccharide type 3 and measurement of IgG3 and IgG3 in 42–56-DAB SPF mice (ten Jbo/+, ten +/-) [40]. For FACS analysis whole blood was collected in lithium heparin tubes from the jugular vein after overdosing mice with barbiturate-administered IP. SPF mice were assessed at 20–22 DAB (17 Jbo/+, 20 +/-) and 49–58 DAB (14 Jbo/+, 14 +/-). FACS analysis of granulocytes was performed after labeling cells with R-PE-labeled Gr-1 and FITC-labeled Mac-1 markers. The Wilcoxon sum-of-ranks test was used to test for statistical differences between Jbo/+ and +/- post-bleed antibody titers and granulocyte parameters.

Supporting Information

Table S1. T-Dependent and T-Independent Responses in Immune-Challenged Wild-Type and Junbo Mice

Found at DOI: 10.1371/journal.pgen.0020149.s001 (35 KB DOC).

Acknowledgments

We thank Dr. Emma Coghill for advice on using the Amera software and Stuart Townsend for assistance with FACS analysis. We also thank the Histology and Pathology teams at Harwell, United Kingdom for processing of specimens.

Author contributions. NP, REHH, HT, ND, AJH, MTC, and SDB conceived and designed the experiments. NP, REHH, HT, HTT, DB, SM, ZL, FM, MF, PG, AMW, SP, IB, TAH, and MTC performed the experiments. NP, REHH, HT, HTT, DB, SM, ZL, FM, ND, and MTC analyzed the data. MF, PG, AMW, and SP contributed reagents/materials/analysis tools. NP, REHH, MTC, and SDB wrote the paper. Funding. This work was supported by the Medical Research Council, United Kingdom. Hilda Tatsosian is supported by the Eumorphia program (European Commission contract QPG2-CT-2002-00930).

Competing interests. Part of this work was funded by GlaxoSmithKline.
References


